Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 09, 2016 1:06 AM ET

Healthcare Providers and Services

Company Overview of Fox Chase Cancer Center

Company Overview

Fox Chase Cancer Center owns and operates a cancer care hospital in Philadelphia. It offers surgery, radiation oncology, virtual colonoscopy, diagnostic imaging, and breast imaging center of excellence seal services; and develops various therapies and technologies for treating cancer. The company also provides breast evaluation, risk assessment, and cancer education services; and conducts basic, translational, and clinical research with special programs in cancer prevention, detection, survivorship, and community outreach. In addition, it offers fellowship training in breast cancer, hematology, pathology, surgical oncology, advanced minimally invasive thoracic surgery, and urologic oncology....

333 Cottman Avenue

Philadelphia, PA 19111-2497

United States

Founded in 1904





Key Executives for Fox Chase Cancer Center

Chief Executive Officer, President and Cancer Center Director
Chief Financial Officer
Chief Operating Officer
President of Friends of The Hospital
President of Fox Chase Chapter
Compensation as of Fiscal Year 2015.

Fox Chase Cancer Center Key Developments

Fox Chase Report Earnings Results for the Year Ended June 30, 2015

Fox Chase reported earnings results for the year ended June 30, 2015. For the year, the company had an operating profit of $11.3 million in the year ended June 30 compared to an $18.5 million operating loss the year before.

Horizon Pharma plc Announces Collaboration with Fox Chase Cancer Center to Study ACTIMMUNE (interferon Gamma 1b) in Combination with PD-1/PD-L1 Inhibitors in Various Forms of Cancer

Horizon Pharma plc announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma. Preclinical cell line research has indicated that interferon gamma enhances cellular PD-L1 expression on endothelial cells (inner lining of the blood vessel) and on some tumor cells. By enhancing cellular PD-L1 expression on tumor cells, interferon gamma may promote or enhance the effect of the PD-1 or PD-L1 inhibitors. The first study being planned as part of the collaboration will be a dose-ranging study to determine a suitable dose for ACTIMMUNE with PD-1/PD-L1 inhibition. Once the ideal combination strategy is determined, the investigators intend to expand the study to include patients with metastatic bladder and renal cell carcinomas. Additional studies are expected to follow depending on initial results.

Oncoceutics and Fox Chase Cancer Center Announce an Agreement to Conduct Clinical Testing with ONC201

Oncoceutics and Fox Chase Cancer Center have announced an agreement to conduct clinical testing with ONC201, a novel first-in-class small molecule compound being developed by the company. The study led by Dr. Anthony Olszanski, director of the Phase I Experimental Therapeutics Program at Fox Chase Cancer Center, will systematically assess dose escalation with three different schedules for oral ONC201 ranging from every three week to one week administration. ONC201 showed a benign safety profile, as well as early signs of activity, at therapeutic doses in the first Phase I study conducted at the Cancer Institute of New Jersey. The clinical trial at Fox Chase Cancer Center makes use of the excellent tolerability of ONC201 and recent preclinical data generated at Fox Chase Cancer Center that suggests single agent ONC201 has profound antitumor activity that, in certain circumstances, can be further optimized when given more frequently. The strong tumor-depleting activity as a single agent is a feature that is facilitated by its ability to eliminate cancer stem cells and spare normal cells. The clinical study is part of a larger academic/corporate partnership between Fox Chase Cancer Center and Oncoceutics. This close relationship is rooted in a long history of Dr. Wafik El-Deiry's research on cell death pathways that allow cancer cells to escape the lethal effects of anti-cancer drugs. ONC201 emerged from laboratory research in his group as a first-in-class oral compound that is effective in a broad spectrum of tumor types that are being evaluated in the clinic. Dr. El-Deiry is a Professor of Medical Oncology, Deputy Director for Translational Research and co-Leader of the Molecular Therapeutics Program at Fox Chase Cancer Center. He is also an American Cancer Society Research Professor and the Scientific Founder of Oncoceutics.

Similar Private Companies By Industry

Company Name Region
AbilTo, Inc. United States
Lexington Memorial Hospital, Inc. United States
Critical Care Systems, Inc. United States
VHS of Michigan, Inc. United States
Sun Healthcare United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fox Chase Cancer Center, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at